Screener
Novavax NVAX Balance Sheet Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $191.46M-24.5% | $228.36M-13.3% | $240.63M-54.6% | $268.02M-53.3% | $253.74M-62.7% | ||
| $527.88M+47.2% | $561.97M+20.0% | $494.45M+25.9% | $494.87M+47.3% | $358.56M-2.9% | ||
| $10.01M-2.3% | $11.46M+11.6% | $11.55M+32.0% | $13.51M+56.4% | $10.24M+11.6% | ||
| $771.1M-16.1% | $850.82M-2.0% | $978.28M-13.3% | $974.59M-11.7% | $919.51M-23.6% | ||
| $38.13M-70.6% | $42.15M-68.4% | $44.8M-67.6% | $49.12M-82.8% | $129.64M-55.1% | ||
| $112.54M-0.4% | $112.89M+0.8% | $113.46M+5.6% | $113.08M-10.8% | $112.96M-8.4% | ||
| $955.58M-28.5% | $1.04B-19.3% | $1.18B-24.6% | $1.18B-31.1% | $1.34B-26.5% | ||
| $22.94M-54.7% | $16.1M-52.9% | $24.58M-40.9% | $15.23M-73.5% | $50.6M-36.7% | ||
| $86.58M-23.9% | $88.77M-18.1% | $140.05M-79.3% | $104.25M-83.0% | $113.76M-82.9% | ||
| $4.11M-26.0% | $2.11M-61.4% | $2.51M-64.2% | $5.04M-47.9% | $5.55M-41.1% | ||
| $330.57M-15.0% | $342.46M-18.9% | $459.95M-60.2% | $429.87M-63.6% | $389.14M-66.4% | ||
| $291.49M— | $291.04M— | $244.21M— | —— | —— | ||
| $1.15B-11.8% | $1.19B-13.2% | $1.3B-40.3% | $1.34B-40.3% | $1.3B-42.3% | ||
| $1.68M+2.2% | $1.68M+2.2% | $1.65M+1.9% | $1.65M+2.0% | $1.65M+2.0% | ||
| -$4.63B-5.7% | -$4.58B-2.0% | -$4.57B+8.8% | -$4.59B+6.9% | -$4.38B+8.8% | ||
| -$190.71M-607% | -$144.76M-91.4% | -$127.75M+79.5% | -$156.67M+70.2% | $37.63M+109% | ||
| $955.58M-28.5% | $1.04B-19.3% | $1.18B-24.6% | $1.18B-31.1% | $1.34B-26.5% |
FAQ
- What are Novavax's total assets?
- Novavax (NVAX) holds $955.6M in total assets, down 28.5% year over year.
- How much debt does Novavax have?
- Novavax carries $297.3M in total debt against -$190.7M of shareholders' equity, a debt-to-equity ratio of 1.54.
- How much cash does Novavax have?
- Novavax holds $191.5M in cash and equivalents.
- Can Novavax cover its short-term obligations?
- Its current ratio is 2.33 — current assets exceed current liabilities.
- Where does Novavax's balance sheet data come from?
- Every line is extracted from Novavax's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
